A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma.

2.50
Hdl Handle:
http://hdl.handle.net/10541/84089
Title:
A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma.
Authors:
Rohatiner, Ama; Radford, John A ( 0000-0001-7898-2786 ) ; Deakin, David P; Earl, H; Love, S B; Price, O; Wilson, A; Lister, T Andrew
Abstract:
The purpose of this study was to evaluate the role of interferon as initial and maintenance therapy in patients with newly diagnosed follicular lymphoma. Between 1984 and 1994, 204 patients with newly diagnosed Stage III or Stage IV follicular lymphoma were randomized to receive either, Chlorambucil (CB): 10 mg daily for 6 weeks, followed by a 2-week interval, with 3 subsequent 2-week treatment periods at the same dose, separated by 2-week intervals, or, CB given concurrently with interferon (IFN). IFN was given at a dose of 3 x 10(6)units thrice weekly, subcutaneously, throughout the 18-week treatment period. Responding patients were subsequently randomized to receive maintenance IFN at the dose and schedule described above, or to expectant management. The overall response rate was 161/204 (78%), complete remission being achieved in 24% of patients. Neither the addition of IFN to the initial treatment, nor the use of maintenance IFN influenced response rate, remission duration or survival. This study was undertaken to determine whether IFN, given in combination with, and then subsequent to, CB would alter the clinical course of patients with follicular lymphoma. Disappointingly, this objective was not achieved, no advantage having been demonstrated for the addition of IFN.
Affiliation:
ICRF Medical Oncology Unit, St. Bartholomew's Hospital, London, West Smithfield, EC1A 7BE.
Citation:
A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma. 2001, 85 (1):29-35 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
6-Jul-2001
URI:
http://hdl.handle.net/10541/84089
DOI:
10.1054/bjoc.2001.1822
PubMed ID:
11437398
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorRohatiner, Amaen
dc.contributor.authorRadford, John Aen
dc.contributor.authorDeakin, David Pen
dc.contributor.authorEarl, Hen
dc.contributor.authorLove, S Ben
dc.contributor.authorPrice, Oen
dc.contributor.authorWilson, Aen
dc.contributor.authorLister, T Andrewen
dc.date.accessioned2009-10-12T17:16:23Z-
dc.date.available2009-10-12T17:16:23Z-
dc.date.issued2001-07-06-
dc.identifier.citationA randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma. 2001, 85 (1):29-35 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid11437398-
dc.identifier.doi10.1054/bjoc.2001.1822-
dc.identifier.urihttp://hdl.handle.net/10541/84089-
dc.description.abstractThe purpose of this study was to evaluate the role of interferon as initial and maintenance therapy in patients with newly diagnosed follicular lymphoma. Between 1984 and 1994, 204 patients with newly diagnosed Stage III or Stage IV follicular lymphoma were randomized to receive either, Chlorambucil (CB): 10 mg daily for 6 weeks, followed by a 2-week interval, with 3 subsequent 2-week treatment periods at the same dose, separated by 2-week intervals, or, CB given concurrently with interferon (IFN). IFN was given at a dose of 3 x 10(6)units thrice weekly, subcutaneously, throughout the 18-week treatment period. Responding patients were subsequently randomized to receive maintenance IFN at the dose and schedule described above, or to expectant management. The overall response rate was 161/204 (78%), complete remission being achieved in 24% of patients. Neither the addition of IFN to the initial treatment, nor the use of maintenance IFN influenced response rate, remission duration or survival. This study was undertaken to determine whether IFN, given in combination with, and then subsequent to, CB would alter the clinical course of patients with follicular lymphoma. Disappointingly, this objective was not achieved, no advantage having been demonstrated for the addition of IFN.en
dc.language.isoenen
dc.subjectCancer Stagingen
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshAntineoplastic Agents-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshChlorambucil-
dc.subject.meshDisease-Free Survival-
dc.subject.meshDrug Administration Schedule-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshInterferons-
dc.subject.meshLymphoma, Follicular-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Staging-
dc.subject.meshProportional Hazards Models-
dc.subject.meshRemission Induction-
dc.subject.meshSurvival Rate-
dc.titleA randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma.en
dc.typeArticleen
dc.contributor.departmentICRF Medical Oncology Unit, St. Bartholomew's Hospital, London, West Smithfield, EC1A 7BE.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.